Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients

Hiroki Ochiai, Takashi Ohishi, Koji Osumi, Jo Tokuyama, Hidejirou Urakami, Shikou Seki, Atsushi Shimada, Akira Matsui, Yoh Isobe, Yuya Murata, Takashi Endo, Yoshiyuki Ishii, Hirotoshi Hasegawa, Sumio Matsumoto, Yuko Kitagawa

研究成果: Article査読

22 被引用数 (Scopus)

抄録

Purpose: We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007. Methods: S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9). Results: S-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%). Conclusion: The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.

本文言語English
ページ(範囲)164-168
ページ数5
ジャーナルSurgery today
42
2
DOI
出版ステータスPublished - 2012 1月

ASJC Scopus subject areas

  • 外科

フィンガープリント

「Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル